A Randomized Phase III Trial of Checkpoint Blockade in Lung Cancer Patients in the Adjuvant Setting Based on Pathologic Response Following Neoadjuvant Therapy (CLEAR)
Latest Information Update: 11 Apr 2025
At a glance
- Drugs Ceralasertib (Primary) ; Durvalumab (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms CLEAR
Most Recent Events
- 14 Mar 2025 Planned initiation date changed from 14 Mar 2025 to 13 Jun 2025.
- 18 Dec 2024 New trial record